title: Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals.
abstract: A strong overlap exists between gp170 and CYP3A substrates and inducers. In order to investigate a putative coregulation of MDR and CYPA gene expression, we measured their transcripts in human liver and after dexamethasone treatment in HepG2 cells or in different mouse tissues. In human liver, we observed no correlation between MDR1 and CYP3A4 expression, whereas these genes were coinduced by dexamethasone in HepG2 cells. In mouse liver treated with dexamethasone, mdr1b and Cyp3a were induced (5- and 2-fold, respectively). In adrenals, the main expressing gp170 tissue, Cyp3a, was increased while mdr1b was repressed (-51%). The expression of mdr1b increased in heart, brain, and colon and decreased in lung and kidney but Cyp3a was not detectable. In conclusion, human hepatic CYP3A4 and MDR1 are not corregulated but are coinducible. In vivo murine mdr1b and Cyp3a are coregulated by dexamethasone in liver and inversely regulated in adrenals.
authors.affiliation: UPRES-A CNRS 6032, EA 2194 Laboratory of Toxicology, Mediterranean University, 27 Boulevard J Moulin, Marseille, 13385, France. eric.seree@pharmacie.univ-mrs.fr
authors.forename: E
authors.initials: E
authors.lastname: Sérée
authors.forename: P H
authors.initials: PH
authors.lastname: Villard
authors.forename: A
authors.initials: A
authors.lastname: Hevér
authors.forename: N
authors.initials: N
authors.lastname: Guigal
authors.forename: F
authors.initials: F
authors.lastname: Puyoou
authors.forename: B
authors.initials: B
authors.lastname: Charvet
authors.forename: H
authors.initials: H
authors.lastname: Point-Scomma
authors.forename: E
authors.initials: E
authors.lastname: Lechevalier
authors.forename: B
authors.initials: B
authors.lastname: Lacarelle
authors.forename: Y
authors.initials: Y
authors.lastname: Barra
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism*; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases; D001483:Base Sequence; D002460:Cell Line; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000235:genetics*; D017931:DNA Primers / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology*; D004790:Enzyme Induction / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D019450:Genes, MDR / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D010089:Oxidoreductases, N-Demethylating / Q000096:biosynthesis / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014018:Tissue Distribution
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D017931:DNA Primers; D012333:RNA, Messenger; D003907:Dexamethasone; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating